Management of Leukopenia

Initial Assessment and Classification

The management of leukopenia should focus on identifying the underlying cause, assessing severity, and implementing targeted interventions based on the patient's clinical presentation and risk factors 1
Determine the severity of leukopenia - mild leukopenia (low white blood cell count) generally requires monitoring, while severe neutropenia (very low neutrophil count) demands more aggressive management 1
Consider bone marrow aspiration and biopsy if there are concerns for malignancy, particularly in cases with unexplained persistent leukopenia 1

For myelodysplastic CMML with <10% blasts, provide supportive therapy focused on correcting low blood cell counts 2, 1
For myelodysplastic CMML with ≥10% blasts, add hypomethylating agents to supportive care 2, 1
For patients with hairy cell leukemia, purine analogs are the standard treatment but can cause profound and prolonged neutropenia requiring careful monitoring 3
Consider allogeneic stem cell transplantation for eligible patients with high-risk disease, particularly those under 60 years of age 1

For TKI-induced neutropenia in CML patients, temporarily discontinue or reduce treatment based on the specific TKI and severity of neutropenia 4

For febrile neutropenia, obtain blood cultures and other appropriate cultures before initiating antibiotics 1
Consider Colony Stimulating Factors like filgrastim for patients with fever and neutropenia who are at high risk for infection-associated complications 1
High-risk features include profound neutropenia, expected prolonged neutropenia, age >65 years, uncontrolled primary disease, or signs of systemic infection 1

For autoimmune hemolytic anemia or immune thrombocytopenia associated with CLL, initial treatment should be with glucocorticoids, not chemotherapy 5
Second-line treatment options include splenectomy, intravenous immunoglobulins, and/or immunosuppressive therapy 5
Consider rituximab or alemtuzumab for refractory cases 5

G-CSF should be administered according to American Society of Clinical Oncology guidelines during myelosuppressive chemotherapy 5
G-CSF may benefit patients experiencing prolonged cytopenias after alemtuzumab treatment 5
Erythropoiesis stimulating factors may benefit CLL patients with anemia if used according to published guidelines 5
For patients with myelodysplastic-type CMML, myeloid growth factors should be considered only for febrile severe neutropenia 1

In chronic phase CML, monitor blood counts weekly during the first 4-6 weeks of TKI therapy 4
Later, monitor every 2 weeks or monthly until month 3, then every 3 months if stable 4
More frequent monitoring is advised for patients with advanced disease 4
Regular complete blood counts and bone marrow evaluations are necessary to assess disease status in hematologic malignancies 2

Patients with hairy cell leukemia who have previously been treated with purine analogs have profound and persistent lymphopenia and should receive irradiated blood products if transfusion is indicated 3
Screen for previous exposure to hepatitis before therapy for hairy cell leukemia, as immunosuppressive therapy can cause severe liver toxicity through viral reactivation 3
Avoid invasive procedures in severely neutropenic patients due to increased risk of infection 1
Age and comorbidities significantly impact treatment decisions, particularly regarding intensive chemotherapy and transplantation eligibility 2

Don't assume all leukopenia requires treatment; mild cases often need observation only 1
Avoid unnecessary antimicrobial prophylaxis in mild leukopenia to prevent antibiotic resistance 1
Don't modify treatment based solely on incomplete blast maturation detected during follow-up 1
Recognize that dasatinib is more frequently associated with death from sepsis than other TKIs, even at 100 mg once daily 4